Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

Fineline Cube May 11, 2026
Company Drug

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

Fineline Cube May 11, 2026
Company Drug

Lundbeck’s Eptinezumab Launches in Boao Lecheng for Migraine Treatment

Fineline Cube Nov 11, 2022

Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone,...

Company Deals Digital

Novartis Partners with Alibaba Health to Enhance Patient Medication Accessibility

Fineline Cube Nov 11, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss...

Company Drug

RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis

Fineline Cube Nov 11, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...

Company Deals

Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies

Fineline Cube Nov 11, 2022

Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...

Company Drug

CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study

Fineline Cube Nov 11, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...

Company Drug

BeiGene’s Brukinsa Receives Marketing Approval in Brazil

Fineline Cube Nov 11, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...

Company Drug

Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs

Fineline Cube Nov 11, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...

Company Drug

Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study

Fineline Cube Nov 11, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...

Company Drug

3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...

Company Deals

Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab

Fineline Cube Nov 10, 2022

Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...

Company Drug

LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China

Fineline Cube Nov 10, 2022

Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...

Company Deals

Innovex Medical Files for IPO in Hong Kong to Boost Product Development

Fineline Cube Nov 10, 2022

Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed...

Company Drug

NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma

Fineline Cube Nov 10, 2022

The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug,...

Company Drug

Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918

Fineline Cube Nov 10, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...

Policy / Regulatory

China Releases 14th Five-Year Plan for National Health Informatization

Fineline Cube Nov 10, 2022

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and the National Bureau...

Company

Zai Lab Reports 33% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings...

Company Deals

GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline...

Company Drug

3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Boston Scientific Partners with Omron for Atrial Fibrillation Management

Fineline Cube Nov 10, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at...

Company Deals

Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...

Posts pagination

1 … 599 600 601 … 663

Recent updates

  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer
  • CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion
  • NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards
  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

Company Drug

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.